ALS Research and Clinical Trials
Quick Facts
What is the latest in ALS treatment and research?
ALS is a progressive neurodegenerative disease that damages the motor neurons controlling voluntary muscles. Patients typically experience weakness, difficulty speaking and swallowing, and eventually respiratory failure. For decades the only approved disease-modifying drug was riluzole, cleared by the U.S. FDA in the 1990s and associated with a modest survival benefit. Edaravone, approved in 2017 as an intravenous therapy and later made available in an oral form, was the next addition and was shown to slow functional decline in selected patients.
The biggest shift in recent years has been genetic. Tofersen (Qalsody) received accelerated FDA approval in 2023 for ALS caused by mutations in the SOD1 gene. It is an antisense oligonucleotide given into the spinal fluid that reduces production of the toxic SOD1 protein. SOD1-related disease accounts for only a small fraction of ALS, but the approval showed that targeting the genetic cause is feasible. It also encouraged work on other genetic forms, including those involving C9orf72 and FUS. Not every candidate has succeeded: a combination therapy that reached the market in 2022 was later withdrawn after a larger confirmatory trial failed to show benefit, a reminder that early signals can fail to hold up.
How do platform trials speed up ALS drug testing?
ALS is heterogeneous. Patients differ widely in the rate of progression, site of onset and genetic background, which makes conventional trials slow and statistically difficult. The HEALEY ALS Platform Trial, run from Mass General Brigham, was designed to address this. Multiple investigational treatments are evaluated at once under a single master protocol and share placebo participants, so more candidates can be screened quickly and fewer patients are assigned to placebo.
Researchers are also pursuing better biomarkers. Neurofilament levels in blood and spinal fluid can signal neuronal injury and may show whether a treatment is having a biological effect earlier than clinical scales can. Other work includes stratifying patients by genetic subtype, studying neuroinflammation, and testing combinations of therapies. These approaches are promising but still need validation. Results should be judged by controlled trial outcomes rather than preliminary findings.
How can people with ALS find and join clinical trials?
Multidisciplinary ALS clinics, which combine neurology, respiratory care, nutrition, speech therapy and palliative care, are usually the best entry point to research studies. These clinics are associated with better care coordination, and many participate in trials or can refer patients to ones nearby. Eligibility often depends on factors such as time since symptom onset, lung function and genetic status, so earlier referral can widen the options.
Genetic testing is increasingly recommended for people with ALS, including those without a family history, because results may qualify patients for targeted therapies or studies. Patients should discuss the potential benefits, burdens and uncertainty of any trial with their care team. Supportive care such as nutritional support, noninvasive ventilation and symptom management remains important alongside experimental treatment.
Frequently Asked Questions
No. Approved drugs such as riluzole and edaravone modestly slow progression in some patients, and tofersen is approved for SOD1-related ALS. Supportive care also improves quality of life.
Many experts recommend it, even without a family history, because identifying a mutation such as SOD1 can open access to targeted therapy and genetic-specific trials. A genetic counselor can help interpret results.
A platform trial evaluates several treatments under one shared protocol, often with a common placebo group. This lets researchers test more candidates faster and with fewer placebo recipients.
References
- Mass General Brigham. What's the Latest on ALS Research and Clinical Trials? (news coverage reviewed November 2026).
- U.S. Food and Drug Administration. FDA approval of Qalsody (tofersen) for SOD1-ALS. 2023.
- U.S. Food and Drug Administration. Riluzole and edaravone (Radicava) approval records for amyotrophic lateral sclerosis.